Anti-tumor necrosis factor-alpha-induced psoriasis.

SARI İ., Akar S., Birlik M., Sis B., Onen F., Akkoc N.

The Journal of rheumatology, vol.33, no.7, pp.1411-4, 2006 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 33 Issue: 7
  • Publication Date: 2006
  • Journal Name: The Journal of rheumatology
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Page Numbers: pp.1411-4
  • Keywords: tumor necrosis factor-alpha inhibitors, psoriasis, adverse effect, ANKYLOSING-SPONDYLITIS, RHEUMATOID-ARTHRITIS, NEW-ONSET, EXACERBATION, THERAPY, CLASSIFICATION, INFLIXIMAB, CRITERIA, LESIONS, AGENTS
  • Dokuz Eylül University Affiliated: Yes

Abstract

We describe a patient with rheumatoid arthritis who developed psoriasis during treatment with etanercept; psoriatic lesions resolved completely after the drug was discontinued. but returned on rechallenge. No such adverse skin reaction occurred after switching therapy to infliximab. Through a Medline search we identified 11 reports involving 32 patients who developed psoriasis/psoriasiform eruptions during therapy with tumor necrosis factor-alpha (TNF-alpha) inhibitors. All TNF-alpha blocking agents have been reported to lead to or exacerbate psoriasis. In some cases skin changes were severe enough to discontinue the medication.